Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1971 3
1972 1
1973 1
1974 1
1975 3
1976 4
1977 3
1978 5
1979 8
1980 7
1981 7
1982 8
1983 6
1984 5
1985 3
1986 6
1987 4
1988 9
1989 6
1990 9
1991 11
1992 4
1993 2
1994 10
1995 7
1996 7
1997 9
1998 3
1999 5
2000 13
2001 7
2002 14
2003 23
2004 19
2005 23
2006 24
2007 20
2008 28
2009 33
2010 41
2011 25
2012 34
2013 56
2014 59
2015 55
2016 52
2017 51
2018 44
2019 38
2020 43
2021 41
2022 33
2023 24
2024 44
2025 45
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

935 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Spironolactone for heart failure with preserved ejection fraction.
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Pitt B, et al. N Engl J Med. 2014 Apr 10;370(15):1383-92. doi: 10.1056/NEJMoa1313731. N Engl J Med. 2014. PMID: 24716680 Free article. Clinical Trial.
BACKGROUND: Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart failure and a preserved left ventricular ejection fr …
BACKGROUND: Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejec …
Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.
Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, Ryu J, Lee HY, Choi S, Lee EM, Choi JH, Kim KI, Shin J, Pyun WB, Kim DH, Park S, Williams B. Lee CJ, et al. JAMA. 2025 Jun 17;333(23):2073-2082. doi: 10.1001/jama.2025.5129. JAMA. 2025. PMID: 40366680 Free PMC article. Clinical Trial.
IMPORTANCE: Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomized clinical trials have compared the efficacy of spironolactone and amiloride in patients with resistant hypertension. ...There were …
IMPORTANCE: Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomiz …
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. Pitt B, et al. N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001. N Engl J Med. 1999. PMID: 10471456 Free article. Clinical Trial.
A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes. RESULTS: The trial was discontinued early, after a mean follow-up period of 24 months, because an interim a …
A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end …
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Williams B, et al. Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20. Lancet. 2015. PMID: 26414968 Free PMC article. Clinical Trial.
The hierarchical primary endpoints were the difference in averaged home systolic blood pressure between spironolactone and placebo, followed (if significant) by the difference in home systolic blood pressure between spironolactone and the average of the other two ac …
The hierarchical primary endpoints were the difference in averaged home systolic blood pressure between spironolactone and placebo, f …
Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, Pyne S, Ridd MJ, Francis N, Soulsby I, Thomas K, Permyakova N, Little P, Muller I, Nuttall J, Griffiths G, Thomas KS, Layton AM; SAFA trial investigators. Santer M, et al. BMJ. 2023 May 16;381:e074349. doi: 10.1136/bmj-2022-074349. BMJ. 2023. PMID: 37192767 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants were randomly assigned (1:1) to either 50 mg/day spironolactone or matched placebo until week six, increasing to 100 mg/day spironolactone or placebo until week 24. ...Spironolactone is a useful alternative to oral antibiotics for …
INTERVENTIONS: Participants were randomly assigned (1:1) to either 50 mg/day spironolactone or matched placebo until week six, increa …
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.
Kosiborod MN, Cherney DZI, Desai AS, Testani JM, Verma S, Chinnakondepalli K, Dolling D, Patel S, Dahl M, Eudicone JM, Friberg L, Ouwens M, Antunes MO, Connelly KA, Madrini V Jr, Kuthi L, Lala A, Lorenzo M, Guimarães PO, Marcos MC, Merkely B, Nuñez J, Squire I, Václavík J, Wranicz J, Petrie MC. Kosiborod MN, et al. J Am Coll Cardiol. 2025 Mar 18;85(10):971-984. doi: 10.1016/j.jacc.2024.11.014. Epub 2024 Nov 18. J Am Coll Cardiol. 2025. PMID: 39566872 Free article. Clinical Trial.
During open-label run-in, participants underwent spironolactone titration (target: 50 mg/day); those with hyperkalemia started SZC. Participants with normokalemia (potassium: 3.5-5.0 mEq/L) on SZC and spironolactone 25 mg/day were randomized to continued SZC or pla …
During open-label run-in, participants underwent spironolactone titration (target: 50 mg/day); those with hyperkalemia started SZC. P …
Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study.
Dréno B, Nguyen JM, Hainaut E, Machet L, Leccia MT, Beneton N, Claudel JP, Célérier P, Le Moigne M, Le Naour S, Vrignaud F, Poinas A, Dert C, Boisrobert A, Flet L, Korner S, Khammari A. Dréno B, et al. Acta Derm Venereol. 2024 Feb 21;104:adv26002. doi: 10.2340/actadv.v104.26002. Acta Derm Venereol. 2024. PMID: 38380975 Free PMC article. Clinical Trial.
AFAST and ECLA scores, as well as lesion counts always improved more with spironolactone. Patients' quality of life was better with spironolactone at month 4 and month 6. Spironolactone was very well tolerated. This is the first study to show that, in female …
AFAST and ECLA scores, as well as lesion counts always improved more with spironolactone. Patients' quality of life was better with …
Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis.
Elshahat A, Mansour A, Ellabban M, Diaa A, Hassan A, Fawzy A, Saad OA, Abouelmagd M, Eid M, Elaraby A, Elkasaby MH, Abdelaziz A. Elshahat A, et al. BMC Cardiovasc Disord. 2024 Sep 13;24(1):489. doi: 10.1186/s12872-024-04103-7. BMC Cardiovasc Disord. 2024. PMID: 39271992 Free PMC article.
However, the difference in the clinical effects between eplerenone and spironolactone in individuals with HF remains uncertain. We aimed to assess the impact of eplerenone compared to spironolactone on clinical outcomes within the HF population. ...CONCLUSION: Epler …
However, the difference in the clinical effects between eplerenone and spironolactone in individuals with HF remains uncertain. We ai …
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.
Bommareddy K, Hamade H, Lopez-Olivo MA, Wehner M, Tosh T, Barbieri JS. Bommareddy K, et al. JAMA Dermatol. 2022 Mar 1;158(3):275-282. doi: 10.1001/jamadermatol.2021.5866. JAMA Dermatol. 2022. PMID: 35138351 Free PMC article.
However, spironolactone carries an official warning from the US Food and Drug Administration regarding potential for tumorigenicity. ...There was an association between spironolactone use and decreased risk of prostate cancer (RR, 0.79; 95% CI, 0.68-0.90; certainty …
However, spironolactone carries an official warning from the US Food and Drug Administration regarding potential for tumorigenicity. …
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J, Kim S, Kwon J, Jones L, Hirst JA, Yu LM, Mort S; BARACK-D Investigators; BARACK-D Investigators; Regional coordinating centre teams. Hobbs FDR, et al. Nat Med. 2024 Dec;30(12):3634-3645. doi: 10.1038/s41591-024-03263-5. Epub 2024 Sep 30. Nat Med. 2024. PMID: 39349629 Free PMC article. Clinical Trial.
Two-thirds of participants randomized to spironolactone stopped treatment within 6 months, predominantly because they met prespecified safety stop criteria. ...Spironolactone should not be used for people with stage 3b CKD without another explicit treatment indicati …
Two-thirds of participants randomized to spironolactone stopped treatment within 6 months, predominantly because they met prespecifie …
935 results